Nature Communications (Jun 2021)

A multicentre validation study of the diagnostic value of plasma neurofilament light

  • Nicholas J. Ashton,
  • Shorena Janelidze,
  • Ahmad Al Khleifat,
  • Antoine Leuzy,
  • Emma L. van der Ende,
  • Thomas K. Karikari,
  • Andrea L. Benedet,
  • Tharick A. Pascoal,
  • Alberto Lleó,
  • Lucilla Parnetti,
  • Daniela Galimberti,
  • Laura Bonanni,
  • Andrea Pilotto,
  • Alessandro Padovani,
  • Jan Lycke,
  • Lenka Novakova,
  • Markus Axelsson,
  • Latha Velayudhan,
  • Gil D. Rabinovici,
  • Bruce Miller,
  • Carmine Pariante,
  • Naghmeh Nikkheslat,
  • Susan M. Resnick,
  • Madhav Thambisetty,
  • Michael Schöll,
  • Gorka Fernández-Eulate,
  • Francisco J. Gil-Bea,
  • Adolfo López de Munain,
  • Ammar Al-Chalabi,
  • Pedro Rosa-Neto,
  • Andre Strydom,
  • Per Svenningsson,
  • Erik Stomrud,
  • Alexander Santillo,
  • Dag Aarsland,
  • John C. van Swieten,
  • Sebastian Palmqvist,
  • Henrik Zetterberg,
  • Kaj Blennow,
  • Abdul Hye,
  • Oskar Hansson

DOI
https://doi.org/10.1038/s41467-021-23620-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Cerebrospinal fluid neurofilament light (NfL) is a biomarker for neurodegeneration that can also be assessed in blood. Here the authors show in a validation study the potential for plasma NfL as a biomarker for several neurodegenerative diseases.